About Fibronostics
Fibronostics is a company based in Orlando (United States) founded in 2015. Fibronostics has raised $14.5 million across 2 funding rounds from investors including AT Capital and Elev8.vc. Fibronostics offers products and services including LIVERFASt™ and LIVERSTAT. Fibronostics operates in a competitive market with competitors including Viz.ai, PathAI, Deepcell, Aignostics and Definiens, among others.
- Headquarter Orlando, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$14.5 M (USD)
in 2 rounds
-
Latest Funding Round
$6.5 M (USD), Series A
Jun 15, 2022
-
Investors
AT Capital
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fibronostics
Fibronostics offers a comprehensive portfolio of products and services, including LIVERFASt™ and LIVERSTAT.
Blood-based test assessing liver fibrosis, activity, and steatosis via biomarkers.
Platform for liver health tracking using patient data and analytics.
Funding Insights of Fibronostics
Fibronostics has successfully raised a total of $14.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.5 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $6.5M
-
First Round
First Round
(24 Aug 2020)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series A - Fibronostics | Valuation |
investors |
|
| Aug, 2020 | Amount | Series A - Fibronostics | Valuation | AT Capital Group , Elev8 |
|
Investors in Fibronostics
Fibronostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include AT Capital and Elev8.vc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in multiple sectors are managed by AT Capital Group.
|
Founded Year | Domain | Location | |
|
Venture capital is provided to early-stage technology startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fibronostics
Financial Statements - Fibronostics
Fibronostics Comparisons
Competitors of Fibronostics
Fibronostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viz.ai, PathAI, Deepcell, Aignostics and Definiens, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| domain | founded_year | HQ Location |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| domain | founded_year | HQ Location |
AI-powered single cell classification and isolation technology for clinical research
|
|
| domain | founded_year | HQ Location |
AI-based pathology diagnostic software is provided for medical analysis.
|
|
| domain | founded_year | HQ Location |
Provides image analysis and data mining solutions for quantitative digital pathology in the healthcare industry
|
|
| domain | founded_year | HQ Location |
Digital pathology software is developed for clinical and veterinary productivity.
|
Frequently Asked Questions about Fibronostics
Fibronostics was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Fibronostics is headquartered in Orlando, United States. It is registered at Orlando, Florida, United States.
Fibronostics is a funded company, having raised a total of $14.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8M, raised on Aug 24, 2020.
Fibronostics was established in 2015 in Orlando, United States, within the healthcare diagnostics sector. Machine learning algorithms are utilized to examine subclinical biomarker profiles in plasma, targeting physiological and pathological processes for disease diagnosis and prognosis. Focus areas include cardiometabolic diseases, idiopathic pulmonary fibrosis, and chronic renal conditions, with non-invasive approaches applied across operations.
Fibronostics's top competitors include Aignostics, Deciphex and Pictor Labs.
Fibronostics offers LIVERFASt™ and LIVERSTAT.
Fibronostics has 2 investors. Key investors include AT Capital, and Elev8.vc.